Table 2.
Systemic treatment lines and outcome evaluable for six patients after detection of the acquired BRAF mutation.
| Patient ID | BRAF mutation | Time to detection of BRAF mutation after diagnosis (months) | Treatment after detection of BRAF mutation | TTD (days) | OS (days) | Outcome | |
|---|---|---|---|---|---|---|---|
| 01 | V600E | (Class I) | 96 | Dabrafenib+trametinib (1 L) | 74 | 636 | Alive |
| Osimertinib+dabrafenib (2 L) | 27 | ||||||
| Afatinib+crizotinib (3 L) | 65 | ||||||
| Osimertinib+dabrafenib + (4 L) trametinib | 288 | ||||||
| Osimertinib+bevacizumab (5 L) | 53 | ||||||
| Afatinib+crizotinib (6 L) | 105 | ||||||
| Osimertinib+dabrafenib + (7 L) trametinib | na | ||||||
| 04 | V600E | (Class I) | 47 | Dabrafenib+trametinib (1 L) | 38 | 287 | Deceased |
| Osimertinib+dabrafenib (2 L) | 93 | ||||||
| Osimertinib+dabrafenib + (3 L) trametinib | 77 | ||||||
| Osimertinib+carboplatin + (4 L) | 75 | ||||||
| Pemetrexed+bevacizumab osimertinib+TACE (5 L) | na | ||||||
| 12 | V600E | (Class I) | 38 | Carboplatin+paclitaxel + (1 L) bevacizumab | 68 | 101 | Deceased |
| 13 | K601E | (Class II) | 26 | Osimertinib+paclitaxel (1 L) | 50 | 239 | Deceased |
| 14 | V600E | (Class I) | 34 | Osimertinib+bevacizumab (1 L), carboplatin+gemcitabine (2 L) | 92, 40 | 359 | Deceased |
| 15 | V600E | (Class I) | 51 | Osimertinib+bevacizumab (1 L) carboplatin+paclitaxel + (2 L) bevacizumab | 57, 163 | 219 | Deceased |
BRAFV600E and BRAFK601E mutations result in an increased BRAF kinase activity. See also Fig. 1c for the Kaplan–Meier curve of OS. TTD time-to-treatment discontinuation, OS overall survival: time from acquired resistance (date of biopsy) until death/last day of follow-up, TACE transarterial chemoembolization.